CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Feb. 29, 2020 |
Feb. 28, 2019 |
Feb. 29, 2020 |
Feb. 28, 2019 |
|
| Income Statement [Abstract] | ||||
| Revenue (Note 14) | $ 107,299 | $ 15,349 | $ 169,381 | $ 37,558 |
| Cost of Goods Sold | 58,106 | 2,690 | 65,959 | 4,848 |
| Gross profit | 49,193 | 12,659 | 103,422 | 32,710 |
| Expenses | ||||
| Accounting and audit | 7,493 | 17,495 | 26,529 | 27,067 |
| Depreciation and amortization (Note 9, 10) | 28,282 | 10,086 | 55,794 | 11,689 |
| Advertising and promotions | 34,717 | 113,229 | 80,985 | 285,142 |
| Consulting (Notes 12, 13, 15) | 521,228 | 603,427 | 1,005,024 | 846,418 |
| Investor relation | 3,762 | 21,277 | ||
| Legal and professional | 88,002 | 257,381 | 140,357 | 354,033 |
| Office and miscellaneous | 65,100 | 52,258 | 139,127 | 125,160 |
| Research and development | 186,557 | 66,083 | 294,020 | 163,056 |
| Travel | 21,759 | 20,293 | 43,612 | 39,499 |
| Wages and salaries | 90,768 | 25,627 | 178,361 | 25,627 |
| Unrealized Loss on marketable securities (Note 19) | (983) | (109) | 40,591 | 9,521 |
| Total Operating Expenses | 1,046,685 | 1,165,770 | 2,025,677 | 1,887,212 |
| Net loss and comprehensive loss for the period | (997,492) | (1,153,111) | (1,922,255) | (1,854,502) |
| Net loss and comprehensive loss attributable to: | ||||
| Common shareholders | (950,344) | (1,147,976) | (1,857,657) | (1,849,367) |
| Non-controlling interest | $ (47,148) | $ (5,135) | $ (64,598) | $ (5,135) |
| Basic and diluted loss per share (in dollars per share) | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.02) |
| Weighted average number of common shares outstanding | ||||
| - Basic and diluted (in shares) | 79,890,378 | 77,101,038 | 79,890,378 | 76,079,651 |
| X | ||||||||||
- Definition The aggregate costs related to Consulting. No definition available.
|
| X | ||||||||||
- Definition Investor relations No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Expenses incurred for travel and entertainment during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- References No definition available.
|